Follow the Marijuana Co of America, Inc. stock price and the full insider trade history of the company, a publicly traded company based in United States. Shares trade on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Marijuana Co of America, Inc. has published 2 insider filings. Market capitalisation: €2.2m. The latest transaction was reported on 29 November 2021 (Cession). Among the most active insiders: Quintero Jesus. Every trade is accessible without an account.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
2 of 2 declarations
Marijuana Co of America, Inc. is a U.S. micro-cap company operating in the cannabis and hemp space, and it is not a NYSE/NASDAQ large-cap story but rather a speculative small-company name in the U.S. public markets ecosystem. For French, Belgian, and Swiss investors, the company should be viewed primarily through the lens of regulation, financing risk, and execution risk. Historically, the business is a Utah corporation that pivoted its strategy in 2015 toward cannabis and legal hemp, and its principal business address has been disclosed in Los Angeles, California. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1078799/000107997322000450/mcoa_rega.htm?utm_source=openai)) The company’s SEC disclosures describe a business model built around two main pillars. First, MCOA has presented itself as an owner/operator of cannabis cultivation, processing, and dispensary facilities. Second, and more importantly from a commercial perspective, it has developed a hemp/CBD distribution platform through its wholly owned subsidiary cDistro, Inc., a Nevada corporation. According to the company’s filings and press materials, cDistro distributes hemp-derived cannabinoid products across the United States and supplies wholesalers, convenience stores, specialty retailers, and smoke/vape-related channels in North America. In practical terms, this makes the company more of a distribution-and-brands play than a scaled integrated cannabis operator. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1078799/000107997322000450/mcoa_rega.htm?utm_source=openai)) From a competitive standpoint, Marijuana Co of America remains a very small participant in a crowded U.S. hemp and cannabis market. It competes against much better capitalized public companies, private-label suppliers, and a fragmented wholesale channel. Its competitive edge, if any, is not scale but niche positioning, brand-building ambitions, and the ability to operate within the legal hemp framework under U.S. federal law. The company’s filings emphasize that marijuana remains heavily restricted under federal law, while hemp-derived products below the THC threshold are treated differently. That regulatory split is central to understanding the investment case, because it shapes product legality, interstate distribution, banking access, and partner risk. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1078799/000107997322000450/mcoa_rega.htm?utm_source=openai)) Geographically, the company is U.S.-focused, with operational references centered on Los Angeles and distribution activity across the United States. Its footprint is therefore domestic rather than international, although cDistro’s channel mix touches multiple retail formats in North America. Recent company-specific developments visible in public filings include continued reliance on the cDistro distribution platform and routine SEC reporting, alongside governance changes such as a 2023 board resignation. For investors, the key question is whether MCOA can build sustainable revenue streams and improve operating discipline before dilution, legal complexity, or market volatility erode shareholder value. In short, it is an ultra-small-cap U.S. cannabis/hemp story with high risk, limited scale, and a regulatory backdrop that remains fluid. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1078799/000107997321000583/ex99x1.htm?utm_source=openai))